Compass Therapeutics (CMPX) Enterprise Value (2018 - 2026)

Compass Therapeutics has disclosed Enterprise Value across 9 years of filings, most recently posting -$194.7 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$194.7 million, down 71.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$194.7 million (down 71.98% YoY), and the FY2025 annual result was -$209.5 million, down 64.56% from the prior year.
• Enterprise Value came in at -$194.7 million for Q1 2026 at Compass Therapeutics, up from -$209.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$101.5 million in Q2 2025 to a low of -$219.9 million in Q3 2025.
• The 5-year median for Enterprise Value is -$152.5 million (2023), against an average of -$155.4 million.
• Across the five-year window, Enterprise Value sank 372.95% in 2022 and jumped 35.7% in 2025, its largest moves.
• Compass Therapeutics' Enterprise Value stood at -$186.6 million in 2022, then rose by 18.28% to -$152.5 million in 2023, then gained by 16.51% to -$127.3 million in 2024, then plunged by 64.56% to -$209.5 million in 2025, then rose by 7.06% to -$194.7 million in 2026.
• The last three Enterprise Value figures came in at -$194.7 million (Q1 2026), -$209.5 million (Q4 2025), and -$219.9 million (Q3 2025), per Business Quant data.